Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robbie G Majzner

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Cancer Discovery|March 1, 2023
Reprogramming Cancer into Antigen-Presenting Cells as a Novel ImmunotherapyMiles H Linde, Amy C Fan, Thomas Köhnke, et al.
Science (New York, N.Y.)|November 10, 2022
Enhanced T cell effector activity by targeting the Mediator kinase moduleKatherine A Freitas, Julia A Belk, Elena Sotillo, et al.
Pediatric Blood & Cancer|June 17, 2021
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task ForceSarah B Whittle, Katharine Offer, Ryan D Roberts, et al.
Nature Cancer|October 23, 2025
Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapyMaria Caterina Rotiroti, Aidan M Tousley, Hoyin Chu, et al.
Nature Medicine|April 6, 2023
Tumor inflammation-associated neurotoxicityJasia Mahdi, Jorg Dietrich, Karin Straathof, et al.
Cell|April 28, 2022
Enhanced safety and efficacy of protease-regulated CAR-T cell receptorsLouai Labanieh, Robbie G Majzner, Dorota Klysz, et al.
Science (New York, N.Y.)|April 2, 2021
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodelingEvan W Weber, Kevin R Parker, Elena Sotillo, et al.
Nature Medicine|November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyTerry J Fry, Nirali N Shah, Rimas J Orentas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2019
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain TumorsRobbie G Majzner, Johanna L Theruvath, Anandani Nellan, et al.
Cell|May 13, 2025
Immunotherapy-related cognitive impairment after CAR T cell therapy in miceAnna C Geraghty, Lehi Acosta-Alvarez, Maria C Rotiroti, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Cancer Discovery|March 1, 2023
Reprogramming Cancer into Antigen-Presenting Cells as a Novel ImmunotherapyMiles H Linde, Amy C Fan, Thomas Köhnke, et al.
Science (New York, N.Y.)|November 10, 2022
Enhanced T cell effector activity by targeting the Mediator kinase moduleKatherine A Freitas, Julia A Belk, Elena Sotillo, et al.
Pediatric Blood & Cancer|June 17, 2021
Charting a path for prioritization of novel agents for clinical trials in osteosarcoma: A report from the Children's Oncology Group New Agents for Osteosarcoma Task ForceSarah B Whittle, Katharine Offer, Ryan D Roberts, et al.
Nature Cancer|October 23, 2025
Engineering T cells with a membrane-tethered version of SLP-76 overcomes antigen-low resistance to CAR T cell therapyMaria Caterina Rotiroti, Aidan M Tousley, Hoyin Chu, et al.
Nature Medicine|April 6, 2023
Tumor inflammation-associated neurotoxicityJasia Mahdi, Jorg Dietrich, Karin Straathof, et al.
Cell|April 28, 2022
Enhanced safety and efficacy of protease-regulated CAR-T cell receptorsLouai Labanieh, Robbie G Majzner, Dorota Klysz, et al.
Science (New York, N.Y.)|April 2, 2021
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodelingEvan W Weber, Kevin R Parker, Elena Sotillo, et al.
Nature Medicine|November 21, 2017
CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapyTerry J Fry, Nirali N Shah, Rimas J Orentas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 19, 2019
CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain TumorsRobbie G Majzner, Johanna L Theruvath, Anandani Nellan, et al.
Cell|May 13, 2025
Immunotherapy-related cognitive impairment after CAR T cell therapy in miceAnna C Geraghty, Lehi Acosta-Alvarez, Maria C Rotiroti, et al.
Pageof 6